       Document 0506
 DOCN  M9490506
 TI    Elevated serum levels of a 90,000 daltons tumor-associated antigen in
       cancer and in infection by human immunodeficiency virus (HIV).
 DT    9411
 AU    Natoli C; Ortona L; Tamburrini E; Tinari N; Di Stefano P; D'Egidio M;
       Ghinelli F; Sighinolfi L; D'Ostilio N; Piazza M; et al; Chair of Medical
       Oncology, University G. D'Annunzio Medical; School, Chieti, Italy.
 SO    Anticancer Res. 1994 May-Jun;14(3B):1457-60. Unique Identifier :
       AIDSLINE MED/94346788
 AB    Levels of a 90,000 daltons monoclonal antibody-defined tumor-associated
       antigen, termed 90K, were measured in the serum from 649 patients with
       various types of cancer and 1215 patients infected by the human
       immunodeficiency virus (HIV). Significantly increased 90K serum levels
       (12.1 +/- 0.5 U/ml) were found in cancer patients with respect to
       healthy controls (5.7 +/- 0.3 U/ml), with the highest levels in
       neoplasms of the breast, lung and gastrointestinal tract. In 355
       patients with breast cancer, the elevation of serum 90K levels was more
       pronounced at advanced stages of disease. Mean levels of 90K for 1215
       HIV-infected subjects (21.2 +/- 0.8 U/ml) were significantly higher than
       controls and cancer patients, and the levels progressively increased
       with disease worsening from asymptomatic infection to full blown AIDS.
       These data suggest that 90K is not merely a tumor-associated antigen and
       lead us to postulate it to be a signalling molecule whose production
       might be related to the immune deficit caused by pathogenetic events
       such as neoplastic progression and virus infection.
 DE    Antigens, Neoplasm/*BLOOD  Female  Human  HIV Infections/*BLOOD  Male
       Molecular Weight  Neoplasms/*BLOOD  Prospective Studies  Support,
       Non-U.S. Gov't  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

